Poor Antibody Response After Two Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine in Transplant Recipients

Alessandra Mazzola; Ève Todesco; Sarah Drouin; Fanny Hazan; Stéphane Marot; Dominique Thabut; Shaïda Varnous; Cathia Soulié; Benoı̂t Barrou; Anne‐Geneviève Marcelin; Filomena Conti

doi:10.1093/cid/ciab580

June 22, 2021Clinical Infectious DiseasesOpen Access

Poor Antibody Response After Two Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine in Transplant Recipients

View Full Paper

Ask AI

Bookmark

Share

Key Points

To assess the anti-spike antibody response and clinical safety following two doses of the BNT162b2 SARS-CoV-2 vaccine in solid organ transplant recipients.
Measured anti-spike antibody responses 28 days following the second dose of the BNT162b2 vaccine in 133 solid organ transplant recipients with no prior COVID-19 diagnosis.
Monitored participants for serious adverse events and breakthrough severe COVID-19 infections occurring between or after the two vaccine doses.
A low anti-spike antibody response of 28.6% was observed 28 days after the second vaccine dose among the 133 transplant recipients.
No serious adverse events were recorded during the observation period.
Four severe COVID-19 cases occurred either between or after the two vaccine doses.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Observes a low anti-spike antibody response following two BNT162b2 vaccine doses in solid organ transplant recipients, suggesting the need for revised vaccination strategies.

Abstract

A low anti-spike antibody response of 28.6% was observed 28 days after BNT162b2 vaccine second dose among 133 solid organ transplant recipients without previous coronavirus disease 2019 (COVID-19). No serious adverse events were recorded. Four severe COVID-19 cases were reported between or after the 2 doses. Our data suggest to change the vaccine strategy.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Mazzola et al. (2021) studied this question.

synapsesocial.com/papers/6aa4a1ed1492f90b230a49e6 https://doi.org/10.1093/cid/ciab580

View Full Paper

Ask AI

Bookmark

Share

Poor Antibody Response After Two Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine in Transplant Recipients

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Poor Antibody Response After Two Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine in Transplant Recipients

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading